Novartis reveals more data behind Pluvicto expansion bid

Pharmaphorum

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

pharminent May 18, 2026 (Last updated: May 18, 2026)

Pharmaphorum

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

Related Stories